Currently out of the existing stock ratings of Sean Lavin, 74 are a BUY (74.75%), 25 are a HOLD (25.25%).

Sean Lavin

Work Performance Price Targets & Ratings Chart

Analyst Sean Lavin, currently employed at NOMURA, carries an average stock price target met ratio of 82.71% that have a potential upside of 27.24% achieved within 267 days.

Sean Lavin’s has documented 178 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MASI, Masimo at 26-Feb-2025.

Wall Street Analyst Sean Lavin

Analyst best performing recommendations are on IRTC (IRHYTHM TECHNOLOGIES).
The best stock recommendation documented was for IRTC (IRHYTHM TECHNOLOGIES) at 11/14/2016. The price target of $28 was fulfilled within 4 days with a profit of $3.18 (12.81%) receiving and performance score of 32.03.

Average potential price target upside

of $632500 (63.25%) on HSDT (HELIUS MEDICAL TECHNOLOGIES).
of $41.92 (19.34%) on VAPO (VAPOTHERM).
of $25.59 (32.35%) on MDT (MEDTRONIC PLC).

ABMD ABIOMED ELGX Endologix EXAS EXACT Sciences HOLX Hologic ISRG Intuitive Surgical MDT Medtronic PLC NEO NeoGenomics PODD Insulet SENS Senseonics Holdings TCMD Tactile Systems Technology TRXC Asensus Surgical VAPO Vapotherm AGN Allergan plc ATRC AtriCure BSX Boston Scientific Corp DXCM DexCom HSDT Helius Medical Technologies IRTC iRhythm Technologies VAR Varian Medical Systems EW Edwards Lifesciences Corp MASI Masimo ABT Abbott Laboratories IRT Independence Realty Trust OBLN Obalon Therapeutics OCGN Ocugen RSLS ReShape Lifesciences NEON ONVO Organovo Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Cecilia Furlong